


Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in this application.

Listing of the Claims:

Claims 1-24 (cancelled).

Claim 25 (withdrawn): A compound selected from the group consisting of



or a pharmaceutically acceptable salt thereof.

Claim 26 (previously presented): A method of treating neovascularization in a mammal, comprising administering to a mammal in need thereof, a composition comprising an amount of squalamine or a pharmaceutically acceptable salt thereof effective to treat the neovascularization.

Claim 27 (previously presented): The method according to claim 26, wherein the neovascularization is associated with rheumatoid arthritis.

Claim 28 (previously presented): The method according to claim 26, wherein the administration is selected from the group consisting of intravenous, subcutaneous and intramuscular injection.

Claim 29 (previously presented): The method according to claim 26, wherein the mammal is a human.

Claim 30 (previously presented): A method of treating rheumatoid arthritis in a human, comprising administering to a human in need thereof, a composition comprising an amount of squalamine or a pharmaceutically acceptable salt thereof effective to treat the rheumatoid arthritis.

Claim 31 (previously presented): The method according to claim 26 or claim 30, wherein the composition consists of squalamine.

Claim 32 (previously presented): The method according to claim 26 or claim 30, wherein the composition further comprises one or more pharmaceutically acceptable excipients.